Mohammad Qutub

Dr. Mohammad Qutub

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
MUMilind Janrao Umekar
Milind Janrao Umekar
MQMohammad Qutub
Mohammad Qutub
PSPriyanka Singanwad
Priyanka Singanwad
Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, and the ability to traverse physiological obstacles such as the blood–brain barrier (BBB) and dense tumor stroma. Recent advances in exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) and cargo loading (siRNA, CRISPR-Cas systems, and chemotherapeutics)—have enhanced their precision and therapeutic utility. For CNS delivery, exosomes functionalized with brain-homing peptides (e.g., RVG or TfR ligands) have enabled the efficient transport of neuroprotective agents or gene-editing tools to treat Alzheimer’s disease or glioblastoma. In oncology, engineered exosomes loaded with tumor-suppressive miRNAs or immune checkpoint inhibitors exploit tumor microenvironment (TME) features, such as acidity or enzyme overexpression, for spatially controlled drug release. Furthermore, hybrid exosome–liposome systems and exosome–biomaterial composites are being explored to improve payload capacity and stability. Despite progress, challenges persist in scalable production, batch consistency, and regulatory standardization. This review critically evaluates engineering strategies, preclinical success, and translational hurdles while proposing innovations such as AI-driven exosome design and patient-derived exosome platforms for personalized therapy. By bridging nanotechnology and biomedicine, engineered exosomes can represent a paradigm shift in targeted drug delivery, offering safer and more effective solutions for historically intractable diseases.

12 November 2024 in JCIS Open
Verified
Journal Article
Open access
MQMohammad Qutub
Mohammad Qutub
ATAmol A. Tatode
Amol A. Tatode
TPTanvi Premchandani
Tanvi Premchandani
JTJayshree Taksande
Jayshree Taksande
DMDadaso Mane
Dadaso Mane
MUMilind Umekar
Milind Umekar

31 January 2025 in Nano Trends
Verified
Journal Article
Open access
KPKajol Patil
Kajol Patil
PSPramod S. Salve
Pramod S. Salve
UHUjban Hussain
Ujban Hussain
ATAmol A. Tatode
Amol A. Tatode
MQMohammad Qutub
Mohammad Qutub

7 December 2024 in Journal of Medicine, Surgery, and Public Health
Verified
Journal Article
Open access
ATAmol Tatode
Amol Tatode
PAPranav R. Agrawal
Pranav R. Agrawal
JTJayshree Taksande
Jayshree Taksande
MQMohammad Qutub
Mohammad Qutub
TPTanvi Premchandani
Tanvi Premchandani
KDKishor Danao
Kishor Danao

5 January 2025 in Aspects of Molecular Medicine
Verified
Journal Article
Open access
MQMohammad Qutub
Mohammad Qutub
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
TPTanvi Premchandani
Tanvi Premchandani
MUMilind Umekar
Milind Umekar
DMDadaso Mane
Dadaso Mane

5 November 2025 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
ATAmol Tatode
Amol Tatode
ACAnis Ahmad Chaudhary
Anis Ahmad Chaudhary
MQMohammad Qutub
Mohammad Qutub
RTRashmi Kishoritai Bhoyar College of Trivedi
Rashmi Kishoritai Bhoyar College of Trivedi
MUMilind Umekar
Milind Umekar
TPTanvi Premchandani
Tanvi Premchandani
Colorectal cancer (CRC) progresses through defined stages, from localized carcinoma in situ (Stage 0) to metastatic disease (Stage IV), with treatment strategies evolving from surgery in early stages to systemic therapies in advanced stages. Advances in biomarkers and genomic profiling have enabled personalized approaches, enhancing precision medicine. Nitric oxide (NO) plays a multifaceted role in CRC, acting as both a promoter and an inhibitor of cancer progression depending on its concentration, timing, and cellular context. At low concentrations, NO promotes angiogenesis, enabling tumor growth and metastasis. Conversely, high concentrations can exert anti-tumor effects, including the induction of cell death. Notably, its role in ferroptosis is biphasic: while high, exogenously delivered concentrations of NO can induce this iron-dependent cell death, lower, endogenously regulated levels can be protective by terminating lipid peroxidation. NO influences CRC by modulating the tumor microenvironment, mechanostress responses during metastasis, and signaling through extracellular vesicles (EVs), thereby aiding immune evasion. It also reprograms CRC cell metabolism, enhancing glucose utilization and mitochondrial activity to support growth in hypoxic conditions. The three nitric oxide synthases (NOS)—inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS)—interact with hydrogen sulfide (H 2 S) to regulate oxidative stress and tumor growth. Targeting NO-related processes, such as ferroptosis, metabolic adaptations, and immune modulation, offers promising therapeutic advances to improve CRC treatment outcomes. This review highlights the dual role of NO in CRC, with particular focus on its novel mechanisms in ferroptosis, metabolism, immune modulation, and tumor–microenvironment interactions.